{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:30:01Z","timestamp":1793773801647,"version":"4.6.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,29]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Mass spectrometry (MS) can detect multiple myeloma\u2013derived monoclonal proteins in the peripheral blood (PB) with high sensitivity, potentially serving as a PB assay for measurable residual disease (MRD). This study evaluated the significance of PB MS MRD negativity during posttransplant therapy in patients with newly diagnosed multiple myeloma. Serum samples from 138 patients treated in the phase 3 ATLAS trial of posttransplant maintenance with either carfilzomib, lenalidomide, and dexamethasone, or with lenalidomide alone were analyzed using EXENT MS methodology. We established feasibility of measuring MRD by MS in the PB in the posttransplant setting, despite unavailability of pretreatment calibration samples. There was high agreement between MRD by MS in the PB and paired bone marrow (BM) MRD results at the 10\u20135 threshold, assessed by either next-generation sequencing (NGS) or multiparameter flow cytometry (MFC) (70% and 67%, respectively). Agreement between PB MS and both BM MRD methods was lowest early after transplant and increased with time. MS negativity was associated with improved progression-free survival (PFS), which, in landmark analysis, reached statistical significance after 18 cycles after transplant. Combined PB\/BM MRD negativity by MFC or NGS was associated with superior PFS compared with MRD negativity by only 1 modality. Sustained MS negativity carried similar prognostic performance to sustained BM MRD negativity at the 10\u20135 threshold. Overall, posttransplant MS assessment was feasible and provided additional prognostic information to BM MRD negativity. Further studies are needed to confirm the role and optimal timing of MS in disease evaluation algorithms. The ATLAS trial is registered at www.clinicaltrials.gov as #NCT02659293.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024024041","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T19:55:25Z","timestamp":1715111725000},"page":"955-963","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["Mass spectrometry\u2013based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-1453","authenticated-orcid":false,"given":"Tadeusz","family":"Kubicki","sequence":"first","affiliation":[{"name":"1Section of Hematology\/Oncology, University of Chicago, Chicago, IL"},{"name":"2Pozna\u0144 University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Dytfeld","sequence":"additional","affiliation":[{"name":"2Pozna\u0144 University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Barnidge","sequence":"additional","affiliation":[{"name":"3Binding Site, part of Thermo Fisher, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8430-0120","authenticated-orcid":false,"given":"Dhananjay","family":"Sakrikar","sequence":"additional","affiliation":[{"name":"3Binding Site, part of Thermo Fisher, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7314-8493","authenticated-orcid":false,"given":"Anna","family":"Przyby\u0142owicz-Chalecka","sequence":"additional","affiliation":[{"name":"2Pozna\u0144 University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7207-8534","authenticated-orcid":false,"given":"Krzysztof","family":"Jamroziak","sequence":"additional","affiliation":[{"name":"4Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6078-5415","authenticated-orcid":false,"given":"Pawe\u0142","family":"Robak","sequence":"additional","affiliation":[{"name":"5Medical University of \u0141\u00f3d\u017a, \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Czy\u017c","sequence":"additional","affiliation":[{"name":"6Nicolaus Copernicus University in Toru\u0144, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2067-2715","authenticated-orcid":false,"given":"Agata","family":"Tyczy\u0144ska","sequence":"additional","affiliation":[{"name":"7Medical University of Gda\u0144sk, Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Druzd-Sitek","sequence":"additional","affiliation":[{"name":"8Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Giannopoulos","sequence":"additional","affiliation":[{"name":"9Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Wr\u00f3bel","sequence":"additional","affiliation":[{"name":"10Wroc\u0142aw Medical University, Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Nowicki","sequence":"additional","affiliation":[{"name":"2Pozna\u0144 University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0933-4077","authenticated-orcid":false,"given":"Tomasz","family":"Szczepaniak","sequence":"additional","affiliation":[{"name":"2Pozna\u0144 University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0209-3282","authenticated-orcid":false,"given":"Anna","family":"\u0141ojko-Dankowska","sequence":"additional","affiliation":[{"name":"2Pozna\u0144 University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Matuszak","sequence":"additional","affiliation":[{"name":"2Pozna\u0144 University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gil","sequence":"additional","affiliation":[{"name":"2Pozna\u0144 University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0116-5002","authenticated-orcid":false,"given":"Bartosz","family":"Pu\u0142a","sequence":"additional","affiliation":[{"name":"11Institute of Hematology and Blood Transfusion, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9885-5140","authenticated-orcid":false,"given":"\u0141ukasz","family":"Szukalski","sequence":"additional","affiliation":[{"name":"6Nicolaus Copernicus University in Toru\u0144, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4077-7555","authenticated-orcid":false,"given":"Agnieszka","family":"Ko\u0144ska","sequence":"additional","affiliation":[{"name":"11Institute of Hematology and Blood Transfusion, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0986-8936","authenticated-orcid":false,"given":"Jan Maciej","family":"Zaucha","sequence":"additional","affiliation":[{"name":"7Medical University of Gda\u0144sk, Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-2674","authenticated-orcid":false,"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[{"name":"8Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2806-2583","authenticated-orcid":false,"given":"Damian","family":"Mikulski","sequence":"additional","affiliation":[{"name":"5Medical University of \u0141\u00f3d\u017a, \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Czabak","sequence":"additional","affiliation":[{"name":"12Medical University of Lublin, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"5Medical University of \u0141\u00f3d\u017a, \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Cooperrider","sequence":"additional","affiliation":[{"name":"1Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"1Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin A.","family":"Derman","sequence":"additional","affiliation":[{"name":"1Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2024082915260338400_bib1","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3324\/haematol.2021.280424","article-title":"Improved survival in myeloma patients\u2013a nationwide registry study of 4,647 patients \u226575 years treated in Denmark and Sweden","volume":"108","author":"Moore","year":"2023","journal-title":"Haematologica"},{"issue":"8","key":"2024082915260338400_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk-stratification and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"19","key":"2024082915260338400_bib3","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood.2021012319","article-title":"Validation of the International Myeloma Working Group standard response criteria in the PETHEMA\/GEM2012MENOS65 study: are these times of change?","volume":"138","author":"Jim\u00e9nez-Ubieto","year":"2021","journal-title":"Blood"},{"issue":"23","key":"2024082915260338400_bib4","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2024082915260338400_bib5","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"2024082915260338400_bib6","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2024082915260338400_bib7","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A\u00a0large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2024082915260338400_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol"},{"issue":"25","key":"2024082915260338400_bib9","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024082915260338400_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-020-00911-4","article-title":"Measurable residual disease in multiple myeloma: ready for clinical practice?","volume":"13","author":"Burgos","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"18","key":"2024082915260338400_bib11","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024082915260338400_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients [abstract]","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2024082915260338400_bib13","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","article-title":"Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease-adapted study","volume":"8","author":"Derman","year":"2022","journal-title":"JAMA Oncol"},{"issue":"6","key":"2024082915260338400_bib14","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/CCO.0000000000000987","article-title":"Measurable residual disease in peripheral blood in myeloma: dream or reality","volume":"35","author":"Kubicki","year":"2023","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"2024082915260338400_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2024082915260338400_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-021-00418-2","article-title":"Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation","volume":"11","author":"Derman","year":"2021","journal-title":"Blood Cancer J"},{"issue":"11","key":"2024082915260338400_bib17","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/bloodadvances.2021006762","article-title":"Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma","volume":"6","author":"Puig","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2024082915260338400_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-022-00624-6","article-title":"Mass-fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 \/07LT)","volume":"12","author":"Dispenzieri","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"2024082915260338400_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma","volume":"13","author":"Mai","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"2024082915260338400_bib20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/bjh.16443","article-title":"Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma","volume":"189","author":"Eveillard","year":"2020","journal-title":"Br J Haematol"},{"issue":"9","key":"2024082915260338400_bib21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2024082915260338400_bib22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","article-title":"Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins","volume":"66","author":"Zajec","year":"2020","journal-title":"Clin Chem"},{"issue":"8","key":"2024082915260338400_bib23","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"2024082915260338400_bib24","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"2024082915260338400_bib25","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3390\/diagnostics11101872","article-title":"Harmonization of flow cytometric minimal residual disease assessment in multiple myeloma in centers of polish myeloma consortium","volume":"11","author":"Krzywdzi\u0144ska","year":"2021","journal-title":"Diagnostics"},{"issue":"3","key":"2024082915260338400_bib26","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/pr400985k","article-title":"Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy","volume":"13","author":"Barnidge","year":"2014","journal-title":"J\u00a0Proteome Res"},{"issue":"21","key":"2024082915260338400_bib27","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/rcm.7314","article-title":"Using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry to detect monoclonal immunoglobulin light chains in serum and urine","volume":"29","author":"Barnidge","year":"2015","journal-title":"Rapid Commun Mass Spectrom"},{"key":"2024082915260338400_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jmsacl.2024.02.002","article-title":"Endogenous monoclonal immunoglobulins analyzed using the EXENT\u00ae solution and LC-MS","volume":"32","author":"Barnidge","year":"2024","journal-title":"J\u00a0Mass Spectrom Adv Clin Lab"},{"issue":"7","key":"2024082915260338400_bib29","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1021\/acs.jproteome.9b00705","article-title":"Integrating serum protein electrophoresis with mass spectrometry, a new workflow for M-protein detection and quantification","volume":"19","author":"Zajec","year":"2020","journal-title":"J\u00a0Proteome Res"},{"issue":"1","key":"2024082915260338400_bib30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3324\/haematol.2010.030882","article-title":"Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents","volume":"96","author":"Fern\u00e1ndez de Larrea","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2024082915260338400_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-022-01779-8","article-title":"Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment","volume":"37","author":"Claveau","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"2024082915260338400_bib32","first-page":"380","article-title":"Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma","volume":"193","author":"Abeykoon","year":"2021","journal-title":"Br\u00a0J\u00a0Haematol"},{"issue":"1","key":"2024082915260338400_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-023-00803-z","article-title":"Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry","volume":"13","author":"Noori","year":"2023","journal-title":"Blood Cancer J"},{"issue":"18","key":"2024082915260338400_bib34","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1158\/1078-0432.CCR-21-0649","article-title":"A\u00a0personalized mass spectrometry\u2013based assay to monitor M-protein in patients with\u00a0multiple myeloma (EasyM)","volume":"27","author":"Liyasova","year":"2021","journal-title":"Clin Cancer\u00a0Res"},{"issue":"1","key":"2024082915260338400_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2288-2-8","article-title":"Do multiple outcome measures\u00a0require p-value adjustment?","volume":"2","author":"Feise","year":"2002","journal-title":"BMC Med Res Methodol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/9\/955\/2239968\/blood_bld-2024-024041-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/9\/955\/2239968\/blood_bld-2024-024041-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:34:05Z","timestamp":1724945645000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/9\/955\/516032\/Mass-spectrometry-based-assessment-of-M-protein-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,8,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024041","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}